STXS Stereotaxis, Inc.
Electromedical & Electrotherapeutic Apparatus · NYSE · SEC CIK 1289340 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.8%
TTM net income YoY5.4%
TTM EPS YoY14.3%
Revenue 3-yr CAGR2.2%
Net income 3-yr CAGR—
Margins
Gross margin52.5%
Operating margin-71.9%
Net margin-70.9%
FCF margin-49.2%
EBITDA margin-69.6%
Returns
ROE-161.7%
ROA-35.0%
ROIC (approx.)-229.4%
Asset turnover0.49x
Leverage & solvency
Liabilities / assets67.7%
Debt / equity0.12x
Current ratio1.08x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.68x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $8.93M | $7.67M | $6.29M | $8.64M | $7.46M | $8.80M | $7.47M | $6.34M |
| Cost of revenue | $4.97M | $3.18M | $2.50M | $4.32M | $3.36M | $4.22M | $3.41M | $3.12M |
| Gross profit | $3.96M | $4.49M | $3.79M | $4.33M | $4.10M | $4.58M | $4.06M | $3.22M |
| R&D expense | $3.52M | $2.39M | $2.40M | $2.71M | $2.55M | $1.78M | $2.35M | $2.79M |
| SG&A expense | $4.05M | $4.07M | $4.76M | $4.17M | $5.18M | $4.00M | $4.50M | $5.14M |
| Operating income | -$6.47M | -$4.57M | -$5.98M | -$5.65M | -$6.56M | -$3.98M | -$5.93M | -$7.63M |
| Interest expense | $44,000 | — | — | — | — | — | — | — |
| Net income | -$6.48M | -$4.47M | -$5.86M | -$5.53M | -$6.46M | -$3.83M | -$5.82M | -$7.51M |
| EBITDA | -$6.24M | -$4.40M | -$5.82M | -$5.49M | -$6.40M | -$3.82M | -$5.77M | -$7.47M |
| EPS (basic) | -0.07 | -0.05 | -0.06 | — | -0.07 | -0.05 | -0.07 | — |
| EPS (diluted) | -0.07 | -0.05 | -0.06 | — | -0.07 | -0.05 | -0.07 | — |
| Weighted avg. shares (diluted) | 102.55M | 100.03M | 98.89M | — | 92.01M | 87.95M | 87.77M | — |
| Banking | ||||||||
| Net interest income | $75,000 | $100,000 | $125,000 | $118,000 | $91,000 | $152,000 | $106,000 | $114,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $3.98M | $10.49M | $14.62M | $13.42M | $10.51M | $6.97M | $10.60M | $12.22M |
| Short-term investments | $0 | $0 | — | $0 | $0 | — | — | $0 |
| Receivables | $5.58M | $7.55M | $5.30M | $5.85M | $5.33M | $4.39M | $4.32M | $3.82M |
| Inventory | $13.27M | $12.52M | $10.49M | $9.57M | $10.15M | $9.61M | $9.81M | $8.33M |
| Current assets | $34.44M | $37.99M | $36.03M | $33.85M | $26.66M | $21.90M | $25.91M | $26.44M |
| PP&E, net | $4.12M | $2.88M | $2.96M | $3.02M | $3.16M | $3.28M | $3.44M | $3.57M |
| Goodwill | $29.28M | $3.76M | $3.76M | $3.76M | $3.76M | $3.76M | $3.76M | $3.76M |
| Intangibles | $6.99M | $5.96M | $6.19M | $6.43M | $6.67M | $6.90M | $7.14M | $7.36M |
| Total assets | $82.11M | $55.58M | $54.03M | $52.25M | $45.59M | $41.17M | $45.70M | $46.72M |
| Current liabilities | $31.76M | $26.80M | $23.09M | $22.36M | $20.37M | $20.75M | $24.23M | $21.60M |
| Short-term debt | $548,000 | — | — | — | — | — | — | — |
| Long-term debt | $1.92M | — | — | — | — | — | — | — |
| Total debt | $2.47M | — | — | — | — | — | — | — |
| Total liabilities | $55.58M | $38.10M | $34.43M | $33.53M | $34.05M | $34.42M | $37.53M | $35.29M |
| Shareholders' equity | $21.36M | $12.24M | $14.36M | $13.48M | $6.27M | $1.46M | $2.88M | $6.08M |
| Net debt | -$1.51M | — | — | — | — | — | — | — |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.18M | -$3.67M | -$3.44M | -$3.97M | -$4.20M | -$3.73M | -$1.78M | $1.27M |
| Capital expenditure | $27,000 | $64,000 | $79,000 | $70,000 | $0 | — | — | $2,000 |
| Free cash flow | -$4.20M | -$3.74M | -$3.52M | -$4.04M | -$4.20M | — | — | $1.26M |
| Investing cash flow | -$2.95M | -$1.15M | -$79,000 | -$70,000 | $0 | — | — | -$2,000 |
| Financing cash flow | $614,000 | $695,000 | $4.72M | $6.95M | $7.74M | $34,000 | $32,000 | $159,000 |
| Depreciation & amortization | $230,000 | $171,000 | $159,000 | $158,000 | $156,000 | $156,000 | $156,000 | $159,000 |
| Stock-based compensation | $1.69M | $1.61M | $2.11M | $2.45M | $2.50M | $2.37M | $2.54M | $2.57M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.